Introduction
The developing inner ear takes its origin from a simple otic vesicle that gives rise to the complex three dimensional organs of hearing and balance. This process is dependent fi rst on inductive signals from mesoderm and hindbrain neuroectoderm, and subsequently on reciprocal interactions between otic epithelium and its surrounding periotic mesenchyme. Retinoic acid, a biologically active derivative of vitamin A, is essential to both these inductive morphogenetic events. However, the normal function of retinoic acid in guiding inner ear development is achieved only at homeostatic concentrations. Deviations from optimal retinoid levels, either in excess or defi ciency, results in inner ear dysmorphogenesis.
Approximately one-third of the cases of hearing loss due to congenital inner ear malformations are attributed to non-hereditary factors, including those due to environmental factors, such as exposure to teratogenic agents, or in the case of low and middle income countries, inadequate nutrition. Retinoic acid falls into both these categories. Infants born to mothers exposed to oral retinoids during a critical period of development have a 25-fold increased risk for craniofacial malformations [1] , while an estimated 124 million children are affected each year by vitamin A defi ciency, increasing their risk for congenital anomalies [2, 3, 4] . Pathological effects produced in the inner ear by conditions of vitamin A defi ciency or in utero exposure to excess retinoids (e.g. 13-cis-retinoic acid) [5, 6, 7] are associated with impaired inner ear functionality [8, 9] . Maternal exposure to even topical tretinoin (all-trans retinoic acid) during the fi rst trimester has been associated with otic anomalies [10] .
Retinoid mediated inner ear embryopathies have been reproduced in animal models. Rats maintained on diets defi cient in vitamin A, the source of cellular retinoic acid, results in the formation of immature and small otic vesicles typifi ed by atrophy of the sensory epithelium and often caudal location [11] . In some cases, absence of the otic vesicle ensues as a consequence of complete elimination of dietary vitamin A. Vitamin A defi cient quails are characterized by disrupted otocyst development [12] , while mice harboring mutations in retinoid receptors or metabolizing enzymes that lead to defi ciencies in endogenous retinoid signaling exhibit anomalies of the developing inner ear that recapitulate vitamin A defi ciency [13, 14, 15, 16, 17] . Excess retinoic acid is just as harmful for development. At high doses, maternally administered retinoic acid gives rise to abnormal vestibular and cochlear development in the inner ears of mouse, rat and hamster embryos [18, 19, 20] . In zebrafi sh, excess retinoic acid results in the formation of ectopic and supernumerary otic vesicles [21] .
The teratogenicity of retinoid excess and defi ciency underscores the importance of regulating local retinoid concentrations during inner ear development. This review provides an overview of the implications of retinoic acid signaling during inner ear development, the pathways that mediate its effects and the consequences that ensue to critical signaling molecules when retinoid levels deviate from normal, either in excess or defi ciency.
Stage-Dependent Effects of Retinoids
Teratogenic effects of retinoic acid occur at several susceptible phases of embryogenesis [22] . The gamut of otic malformations resulting from exposure to retinoic acid is critically dependent on both the dose of retinoic acid administered and the developmental stage during which the otic primordia are exposed to excess retinoids [18, 20, 22] . This may be due to differential sensitivities of otic structures to retinoids during their formation [22] . Although the focus of this review is the inner ear, a brief overview of how changes in retinoic acid signaling at slightly different stages of development dramatically affect different target tissues in the ear is discussed below.
Middle ear anomalies affecting the malleus, incus, stapes and tympanic ring, for example, are produced by exposure of embryonic mice to retinoic acid within a narrow temporal framework between embryonic age 8.5 to 8.75 days (E8.5 to E8.75) (Fig. 1) [23, 24, 25] . This is the window of time during which cranial neural crest cells reach the fi rst branchial arch [23] , from which middle ear structures originate [26] . Similar anomalies of the ossicles are observed in conjunction with defective formation of Meckel's cartilage when gravid rats are administered retinoids at comparable stages of development [27, 28] . Histological studies of the temporal bone in affected humans are limited, but show similarities to the teratogenetically induced defects in the mouse and rat embryos. Examination of human fetuses born to mothers receiving isotretinoin before and/or during the fi rst weeks of gestation demonstrate a slit-like tympanic cavity, anteriorly shifted or malformed incus, medially displaced or anomalous malleus, and deformities of the stapes [7, 29] . A hypoplastic facial nerve and absence of the chorda tympani nerve and stapedius muscle have been reported [29] . Since the malformed tissues originate from the fi rst and second branchial arches, with the facial nerve also being one of the nerves of those arches, retinoidinduced embryopathies of the middle ear are likely to be due to early effects of retinoic acid on the fi rst and second arches [23] . Middle ear anomalies are consistent with the conductive hearing loss reported in patients with isotretinoin syndrome [30] .
Defects of the external ear commonly ensue, both in animal models and in the developing human, following early exposure to retinoids [28, 31, 32, 6] , and are associated with anomalies of the fi rst branchial arch [33] . The critical period for exposure appears to be two to fi ve weeks postconception in the human, although this may not be clinically exact [32] . The deformities include anotia, aural atresia, microtic, low-placed and dorsally situated pinna, and narrowing of the external auditory canal [28, 29] . Patients with microtia and atresia are usually characterized by conductive hearing loss in the affected ear.
Exposure to retinoids at later developmental stages in the mouse leads to anomalies of the inner ear [18, 20] . In utero exposure to high dose retinoic acid at E9 specifi cally leads to embryopathies of the cochlea, semicircular canals, utricle, saccule, endoymphatic duct, cochleovestibular ganglia and otic capsule. In extreme cases, the inner ear does not advance beyond a cystic-like structure that lacks distinct organization into pars superior and pars inferior portions (vestibular and cochlear portions respectively) (Fig. 2) . These inner ear anomalies are attributed to disruption in the inductive otic epithelial-periotic mesenchymal interactions that initiate at E9-E9.5 and guide development of these cochlear, vestibular and capsular structures [34] . Hindbrain segmentation and Krox-20 expression are not disturbed, suggesting that inner ear dysmorphogenesis by retinoic acid exposure at E9 is not a consequence of hindbrain abnormalities. Retinoic acid-induced inner ear embryopathies in the mouse bear resemblance to clinical fi ndings in patients maternally exposed to isoretinoin during early gestation, in whom hypoplastic semicircular canals, abnormal endolymphatic sacs, utriculosaccule deformities, and dysgenesis of the cochlea have been observed [29, 35] .
How Retinoids Mediate their Effects
To gain insight into how retinoic acid targets inner ear development, it is important to understand the many pathways through which retinoids can exert their pleiotropic control. This control exists at many levels and is inclusive of retinoid binding proteins, retinoid receptors, and synthetic and metabolic enzymatic pathways.
Cellular Retinoid Binding Proteins
The cellular retinoid binding proteins are a family of proteins that participate in control of retinoid signaling and include the cellular retinol binding proteins (CRBP I and II) and the cellular retinoic acid binding proteins (CRABP I and II). Retinol, the circulating form of vitamin A, binds with high affi nity to CRBP I and II whereas retinoic acid specifi cally binds to CRABP I and II [36, 37, 38] . CRABP and CRBP act as the major binding proteins for retinoic acid and retinol during development [39, 40] , and exhibit specific spatio-temporal expression patterns during otic morphogenesis. CRABP is apparent in the otic placode as early as E8, with high levels of transcripts present in the otic pit at E9 (Fig. 3) . CRBP signal is also evident in the epithelium of the E9 otic pit. By E10.5, CRABP I, II, and CRBP I are all present in the developing inner ear. CRABPI is expressed in the periotic mesenchyme but is not visible at this stage (E10.5) in the otocyst itself or the anlagen which derive from it [41, 42] , whereas CRBP I and CRABPII are found in the dorsal and ventral otocyst respectively [42] . Expression of CRBPI, CRABPI and CRABPII persists in sensory structures of the inner ear during subsequent stages of development.
Given the distinct expression patterns of CRBP and CRABP in the inner ear at critical stages of morphogenesis, one would anticipate an important function for these cytoplasmic proteins during development. Prior to the generation of null mutations of these binding proteins, several possible roles were hypothesized. These include a role for CRABP as a shuttle between the cell cytoplasm and nucleus to promote uptake of retinoic acid [43, 44] and the sequestering of free retinoic acid to reduce the amount available for binding to retinoid receptors [45, 46, 47, 48] . CRBPI was suggested to function in the generation of retinoic acid in cells requiring high levels for proper function and in demarcating regions of the inner ear sensory epithelia that possess regenerative capacity [49] . However, various combinations of single, double and triple null mutations of CRABP and CRBP provided no overt indication of inner ear anomaly or changes in auditory brainstem responses [36, 50] . Retinoid binding proteins may thus not be essential for proper development and function of the inner ear. Alternatively, conditions of vitamin A defi ciency might be needed to unmask possible functions of CRBP in the inner ear since CRBPI null mice, when maintained on a vitamin A poor diet, develop a vitamin A defi ciency syndrome [36] . Functional redundancy between CRBPI and recently identified CRBPIII and CRBPIV [51, 52] may also come into play although expression patterns of CRBPIII and CRBPIV have not yet been defi ned in the inner ear [36] .
Retinoic Acid Synthesizing Enzymes
Enzymes that facilitate retinoic acid synthesis contribute to the maintenance of retinoic acid homeostasis. Neither embryonic nor adult animal cells produce retinoic acid de novo. Instead, dietary sources must provide provitamin A carotenoids and retinyl esters which are then converted into retinol [53] . Conversion of inactive retinol into active retinoic acid involves two oxidative reactions: in the fi rst, retinol is oxidized to retinaldehyde by alcohol dehydrogenases, and in the second, retinaldehyde is effi ciently oxidized into retinoic acid by retinaldehyde dehydrogenases (Raldh) [54] .
Of the various isoforms of Raldhs thus far identifi ed [54, 55] , four have been shown to be expressed in the developing inner ear (Raldh 1, 2, 3, 10). Importantly, their expression is confi ned to the otic epithelium, implicating the otic epithelium as a potential source of retinoic acid that may infl uence inner ear development. During early inner ear development (E9.5), expression of Raldh1 and Raldh2 is limited to the dorsal otocyst [36] , with expression of Raldh2 being relatively weak. Subsequently (E10.5-E12.5), Raldh1 is detected in the developing endolymphatic duct, which arises from the dorsal otocyst (Fig. 4) , whereas Raldh2 becomes localized to a restricted lateral quadrant of the E10.5 otocyst [56] . At this developmental stage (E10.5), expression of Raldh3 is restricted to the region of the otocyst adjacent to the forming endolymphatic duct and the ventral otocyst (Fig. 4) . Later in development (E14.5), Raldh1 is found in all three semicircular canals, the endolymphatic duct, and cristae, and Raldh2 to differentiating nonsensory regions of the cochlea and the vestibular region adjacent to the crista ampullaris. As development progresses, so do the expression domains of Raldh3, which now include the medial aspect of the otocyst, the endolymphatic duct, the lateral otocyst near the forming horizontal semicircular canal, and the ventral region of the forming cochlea. Expression of Raldh1 persists at E18.5 in the cristae and the newly developed maculae of the utricle and the saccule [36] . Raldh2 expression is limited to the vestibular portion of the inner ear, the stria vascularis, and Reissner's membrane, whereas Raldh3 is more broadly expressed in the endolymphatic duct, the crista, the saccular and utricular sensory epithelia, the spiral ganglion, and the stria vascularis [36] . Recently identifi ed Raldh10 is expressed in organs involved in endolymph homeostasis, being noted in the inner ear initially in the endolymphatic system and subsequently in the stria vascularis [57] .
Retinoic Acid Metabolizing Enzymes
The distribution and concentration of retinoic acid in the developing embryo is fi nely controlled by the complementary roles of retinoic acid synthesizing and metabolizing enzymes [58] . The Cyp26 group of enzymes (Cyp26A1, -B1, -C1) is part of the cytochrome P450 superfamily of enzymes, and they are specifi cally involved in catalyzing the conversion of retinoic acid into more polar hydroxylated and oxidized derivatives, a step in their metabolic breakdown [53, 59, 60] A function of Cyp26s is to CRABP CRBP 
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Ed G generate the precise pattern of retinoic acid present in the developing mouse embryo [53, 61] . Cyp26A1 and Cyp26B1 are expressed at high levels during early otic development. At E9.5, expression of Cyp26A1 is observed in the caudal region of the otocyst epithelium and in the axial mesenchyme just caudal and ventral to the otocyst. Cyp26B1 is present in the dorsal region of the E9.5 otocyst. By E10.5, expression of Cyp26A1 is strong in the ventral otocyst and mesenchyme surrounding the lateral and ventral otocyst wall, whereas only two focal regions of the lateral otocyst and prospective sensory epithelium continue to express Cyp26B1 (Fig. 5) . Expression of Cyp26A1 continues to be strong in the mesenchyme adjacent to the forming semicircular ducts and ventral portion of the E12.5 inner ear (Fig. 5) , but by E14.5 becomes restricted to the endolymphatic duct and cochlear epithelium. At this point (E14.5-E18.5), Cyp26B1 expression is limited to the sensory epithelium of the saccule, utricle, cristae, and cochlea. With the exception of the endolymphatic duct, Cyp26A1 is no longer evident in the E18.5 inner ear [36] .
Cyp26C1 appears to play a more limited role in inner ear development. At E10.5, Cyp26C1 is present in the mesenchyme caudal to the E10.5 otocyst and in the ventral otocyst epithelium directly adjacent to the Cyp26C1-expressing mesenchyme [36, 58] . Expression of Cyp26C1 continues in the cochlear epithelium of the E12.5 otocyst, however expression becomes negligible by E14.5.
Retinoid Receptors
There are two classes of retinoid receptors, both of which are nuclear receptors and each of which has 3 subtypes: the retinoic acid receptors (RARs; α, β, γ) and the retinoid X receptors (RXR; α, β, γ). These nuclear receptors bind as either RXR homodimers or RAR/RXR heterodimers to retinoic acid response elements (RAREs) on target genes and function to facilitate transcription and gene expression [62, 63] . Distinct, non-overlapping expression domains of all three RAR isoforms are present in the inner ear, beginning in the early otocyst stage and continuing into adulthood [64] . This diverse expression pattern of RARs and RXRs during embryonic development is thought to delineate specifi c domains of retinoic acid action [56] .
Specifi c isoforms of the retinoic acid receptors (RAR) have been detected as early as E10.5 in the developing inner ear (Fig. 6 ). At this stage the β and γ isoforms of RAR are expressed in the periotic mesenchyme surrounding the anlagen of the developing endolymphatic duct. RARα is restricted to a small dorso-lateral area of the otic epithelium. By E12.5, all three RAR isoforms (α, β, γ) display distinct patterns of expression in either the otocyst or the periotic mesenchyme. In brief, RARα is evident throughout the otocyst epithelium, in the medial and lateral periotic mesenchyme, and in the dorsal aspect of the developing hindbrain. RARβ and RARγ expression persists in the condensing mesenchyme of the forming otic capsule [64] , with RARβ also being expressed in the dorso-medial otocyst wall at the site of the presumptive vestibular epithelium. Expression of RARα persists in the cochlear and vestibular portions of the E14.5-E16.5 inner ear, although not as abundantly as previously, and in the organ of Corti until after birth. Between E14.5-E18.5, expression of RARγ remains primarily in the developing otic capsule and RARβ in tissues of mesenchymal origin.
The retinoid X receptors RXRα and RXRβ demonstrate a rather ubiquitous pattern of expression in the modiolus, cochlear sensory epithelium, spiral limbus, and stria vascularis of the E18.5 inner ear. The expression of RXRγ, by contrast, is much more restricted and is most visible in the spiral ganglion and Kolliker's organ [65] . RXR signal (α, β, γ) is not detected in the otic capsule at these developmental ages. Based on the somewhat overlapping expression patterns of the various retinoid receptors in the developing inner ear, functional overlap between the different isoforms would seem a likely possibility. Consistent with this idea, RARα, RARβ, and RARγ null mutant mice did not reveal any morphological inner ear anomalies. This was also the case for RARα/RARβ and RARβ/RARγ double null mutant mice. In contrast, RARα/RARγ double null mutant mice demonstrated severe dysmorphogenesis of the inner ear [64] that will be discussed in further detail in the retinoid defi ciency section that follows.
Changes in Gene Expression by Retinoic Acid Excess
Deviations from optimal concentrations of retinoic acid induce the ear phenotype by modifying the expression of target genes and signaling molecules critical to otic morphogenesis. An overview of key signaling molecules affected by changes in retinoic acid signaling at different stages of development is provided below.
Goosecoid gene expression is altered in the branchial region at E10.5 following maternal retinoic acid treatment at E8 plus 5 hours. This change in goosecoid correlates with specifi c teratogenic effects in the middle ear, most notably affecting the tympanic ring and middle ear ossicles [24] . Modified expression of goosecoid may be associated with an altered population of neural crest derived mesenchymal cells in the branchial arches [25] . Similarly, treatment of zebrafish embryos with retinoic acid leads to anomalies of craniofacial structures originating from neural crest cells in correlation with loss of Dlx expression [66] . Recent studies suggest that retinoic acid teratogenicity derives from modifi ed signaling from the pharyngeal (branchial) arch epithelium, leading to abnormal activation of genes in the cranial neural crest cells [23] . These epithelial signals include endothelin1 (ET-1) and Fgf 8, which in turn induce Dlx gene expression in the incoming neural crest cells of the fi rst arch. The malleus and incus, derived from the fi rst and second branchial arches, and the stapes, a second arch derivative, are malformed or absent in mice with a targeted mutation of ET-1 [67] . Retinoic acid-induced craniofacial anomalies are prevented when whole mouse embryo cultures are treated with folinic acid, which leads to signifi cantly increased expression of ET-1 and dHAND [68] .
The molecular mechanisms underlying the action of retinoic acid on the inner ear are complex. Inner ear anomalies provoked by conditions of excess retinoic acid occur in association with altered Dlx5 signaling of inductive tissue interactions. Downregulation in Dlx5, which participates in signaling from the otic epithelium to surrounding periotic mesenchyme, ensues in the developing mouse inner ear in response to in utero exposure to high dose retinoic acid and in association with inner ear anomalies (Fig. 7) [69] . This change in Dlx5 expression is not a direct response to retinoid signaling, but instead is thought to occur indirectly as a consequence to retinoid-mediated changes in signaling by fi broblast growth factor 3 and −10 (Fgf3 and Fgf10), which are essential to normal inner ear development. This makes sense given that sequence analysis of related Dlx3,−4 reveals elements that resemble retinoic acid response elements (RAREs) but none that match exactly [70] , while the 5' fl anking region of Xenopus Dlx2 does not contain sequences that match consensus RAREs [71] . On the other hand, sequence analysis of the Fgf3 inner ear enhancer demonstrates the presence of several different putative binding sites where retinoid signaling could directly control Fgf3 expression [72] . Potential retinoid binding sites have also been identifi ed in a 4.5-kb fragment of the 5' upstream region of Fgf10 [73] . Targeted deletion of Dlx5 and of Fgf3/Fgf10 leads to inner ear anomalies that resemble some of the anomalies produced by teratogenic levels of retinoic acid [74, 75, 76] . Furthermore, loss of Fgf3 and/or Fgf10 is correlated with downregulation in Dlx5 in the dorsal otic ectoderm, where it is exclusively expressed from E10.5 onward.
Of signifi cance, Dlx5 is expressed in the epithelium of the developing otocyst, but not in the periotic mesenchyme from which the otic capsule forms. This fi nding indicates that anomalous otic capsule development, a consequence of targeted Dlx5 mutation and retinoid exposure, cannot be directly accounted for by loss of Dlx5. Transforming growth factor-beta 1 (TGFβ 1 ), an essential contributor to otic capsule formation [77, 78, 79, 80] , is downregulated in the inner ear both by excess retinoic acid exposure [34] and loss-of-Dlx5-function (Fig. 8) [69, 81] . TGFβ 1 may thus be one of the downstream mediators through which Dlx5 elicits its otic capsule morphogenetic effects. In support of this, supplementation of cultured inner ear mesenchyme and epithelium with TGFβ 1 rescues the cultures from the chondrogenic defects produced by Dlx5 deletion [69] or high dose retinoic acid treatment [34] . Besides TGFβ 1 , exposure to excess retinoic acid interferes with molecular signaling mechanisms downstream of the ligand [82] . When exposed in utero to high dose retinoic acid, malformations of the inner ear are produced that correlate with signifi cant decreases in TGFβ receptor type II (TGFβRII) and Smad2, i.e. a downstream substrate of TGFβ receptor type I (TGFβRI).
Bone morphogenetic protein 4 (BMP4), a member of the TGFβ superfamily, participates in the epithelial-mesenchymal interactions that guide otic capsule chondrogenesis [80, 83] and is subject to retinoic acid control. Repression of BMP4 expression, potentially facilitated by RARγ in the periotic mesenchyme [36, 84] , is evoked in cultured otocyst cells and in chicken otocysts in response to exogenous retinoic acid. BMP4 acts downstream of Dlx5 in semicircular canal formation [81] . Thus retinoid control of BMP4 may be indirectly facilitated by changes in Dlx5 expression. Alternatively, since RAREs have been identifi ed in the promoter region of the BMP4 gene [85] , this control may occur as a direct response to retinoic acid. In the zebrafi sh, BMP signaling activates foxi1 directly and dlx3b indirectly [86] , factors which provide competence to form the inner ear [87, 88] . Exposure to retinoic acid leads to misexpression of foxi1, but does not affect dlx3b expression [89] .
Retinoid Defi ciency and the Inner Ear
Vitamin A defi cient embryos lack an endogenous source of retinoids, and as a result, many developing organs requiring retinoic acid for development are malformed. Retinoid signaling is essential for normal development of the inner ear. In the vitamin A deficient quail, which lacks hindbrain rhombomeres 5-7 (r5-r7), the otic vesicles are typically positioned anterior to the fi rst pair of somites, next to tissue with an r3 identity, with small ectopic vesicles just caudal to the primary otocyst [90] . These ectopic vesicles resemble the ectopic vesicles noted in the vitamin A deficient rat [11] . A reduction or absence of the vestibule-acoustic ganglion and absence of sensory organ development, assessed using markers of presumptive sensory patches, i.e. BMP4, Prox1 and Msx1, has been observed [90] . The ventralmost expression of Dlx5 is reduced and the ventral-lateral otocyst marker SOHo-1 absent in E2.5 vitamin A defi cient embryos, while at E3.5 Pax2 and EphA4 are diminished and ectopically expressed in ventral and dorso-lateral regions of the otocyst respectively.
Offspring of rats maintained on a vitamin A deficient diet (50 μg/all-trans retinoic acid/g) exhibit malformed otic vesicles, whereas embryos from dams fed 25 μg/all-trans retinoic acid/g or less show small immature otic vesicles, one located in the normal location and a second more caudal vesicle [11] . In some cases, where rats are fed only 0.5 μg/all-trans retinoic acid/g, embryos show absence of otic vesicle formation. As the level of retinoic acid is reduced, a loss of caudal hindbrain segmentation is observed and the incidence of otic anomalies increases [11] . Thus otic anomalies may ensue as a secondary consequence of hindbrain abnormalities.
In the mouse, retinoic acid defi ciency due to double null mutation of RARα and RARγ produces inner ears with poorly developed cochleae, absence of semicircular canals, disorganized sensory epithelia and a malformed otic capsule [64] . Analysis of Raldh2 null mutant embryos at earlier developmental stages due to embryonic lethality shows hypoplastic otocysts that are abnormally distant from the hindbrain neuroepithelium [14] . This neuroepithellium (i.e. Raldh2 null) is characterized by only weak expression of Fgf3, suggesting diminished FGF in the hindbrain as a potential indirect cause of the poor otocyst development. However, between E9-E10, FGF3 and FGF10 become expressed in the developing otic cup and vesicle [73, 91, 92] . Treatment of otic explants with pharmacological retinoid signaling inhibitors at E10.5, a timepoint by which the otocyst can develop in vitro even in the absence of the infl uence of the rhombencephalon, also show immature otic vesicles in association with diminished levels of FGF3 and FGF10 expression (Fig. 9) . Thus retinoid embryopathy of the inner ear may also occur independent of an affect of the hindbrain. In the zebrafi sh, loss of retinoic acid signaling leads to reduced otic vesicles with only one small otolith and impaired protrusions of the semicircular canals [89] . This diminution in endogenous retinoic acid, produced by treatment of embryos with a pharmacological inhibitor (4-diethylamino-benzaldehyde), interferes with fgf3 signaling, leading to a signifi cant reduction in its expression in comparison to control embryos [89] .
Conclusion
Retinoic acid is essential to otic morphogenesis, with fi nely controlled regulatory mechanisms in place at many levels. However, when changes in retinoid signaling occur due to deviations in retinoid exposure and/or perturbation in control factors, substantive inner ear defects ensue. Given the myriad of congenital malformations produced by retinoid deficiency and the increased risk for malformations following excess retinoid exposure, identification of the molecular pathways and regulatory networks that underlie retinoid embryopathies remains an important challenge for the future. 
